Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease.

Background & Aims: Patients with inflammatory bowel disease (IBD) are at risk for certain malignancies. We aimed to determine the risk of melanoma and nonmelanoma skin cancer (NMSC) in patients with IBD and how medications affect these risks.

Methods: We performed retrospective cohort and nested case-control studies using administrative data from the LifeLink Health Plan Claims Database from 1997 to 2009.

Fibroblastic rheumatism: a report of 4 cases with potential therapeutic implications.

Background: Fibroblastic rheumatism is a rare dermatoarthropathy characterized by the sudden onset of cutaneous nodules, flexion contractures, and polyarthritis. Histopathology in the correct clinical context confirms the diagnosis. Treatment is based on observational data from single case reports.

Nonmelanoma skin cancer in inflammatory bowel disease: a review.

At least 1 million new cases of nonmelanoma skin cancer (NMSC) are diagnosed in the United States each year and the incidence is increasing. A higher incidence of NMSC in organ transplant recipients on immunosuppression has been documented for some time, and recent studies indicate that patients with inflammatory bowel disease (IBD), particularly those treated with immunosuppressive medications, might also be at higher risk for this condition. In this review we summarize recent data evaluating the associations between immunomodulators, antitumor necrosis factor-α biologic agents and NMSC in patients with IBD and other autoimmune conditions such as rheumatoid arthritis.

Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease.

Background & Aims: Patients with inflammatory bowel disease (IBD) might be at increased risk for certain malignancies. We evaluated the risk of non-melanoma skin cancer (NMSC) in patients with IBD and determined how immunosuppressive and biologic medications affect this risk.

Methods: We performed retrospective cohort and nested case-control studies by using administrative data from PharMetrics Patient Centric Database.

Cutaneous manifestations of internal malignancies: an overview.

A number of cutaneous disorders have been associated with underlying malignancies. This article reviews the clinical and histologic features of paraneoplastic disorders with cutaneous findings, discusses their associations with neoplastic and other related conditions, and recommends appropriate evaluation in this setting. A heightened awareness of these conditions may facilitate the diagnosis of malignancy.

Beta-lactam antibiotic-induced pseudoporphyria.

A case of beta-lactam antibiotic-induced pseudoporphyria is presented. A 24-year-old African American woman with systemic lupus erythematosus and end-stage renal disease on hemodialysis developed tense bullae on her forehead and cheeks after exposure to ampicillin-sulbactam and cefepime. Histologically, the lesions were similar to porphyria cutanea tarda, but without the associated porphyrin abnormalities.